Thu, Apr 17, 2014, 11:12 AM EDT - U.S. Markets close in 4 hrs 48 mins

Recent

% | $
Quotes you view appear here for quick access.

Aethlon Medical, Inc. Message Board

  • robert.vince robert.vince Sep 24, 2013 8:16 AM Flag

    Aethlon Medical Announces the Appointment of Dr. Cicek Gercel-Taylor as Clinical Research Director of Exosome Sciences, Inc.

    SAN DIEGO, Sept. 24, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), announced today that Dr. Cicek Gercel-Taylor has been appointed Clinical Research Director of Exosome Sciences, Inc. (ESI), a wholly-owned diagnostic subsidiary of Aethlon Medical. In this role, Dr. Gercel-Taylor will direct and plan the execution of diagnostic clinical programs and interact with collaborative partners and regulatory authorities.

    Aethlon Medical develops therapeutic devices to address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. The Company is preparing to launch the first U.S. studies of the Aethlon Hemopurifier® as a therapy to address hepatitis c virus (HCV) based on the recent approval of an Investigational Device Exemption (IDE) by the United States Food and Drug Administration (FDA). The Hemopurifier® is a first-in-class device that targets the rapid elimination of viruses and cancer glycopathogens, including disease-promoting exosomes from circulation.

    Exosome Sciences was recently launched by Aethlon to be a stand-alone organization that pursues exosome-based strategies to diagnose and monitor the progression of cancer, infectious disease and other life-threatening conditions. ESI's lead product, an Enzyme Linked Lectin Specific Assay (ELLSA) has been validated to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal.

    Dr. Gercel-Taylor stated, "I am very excited to join Exosome Sciences as the Clinical Research Director. This is a very timely opportunity to develop clinically relevant exosome-based assays to enhance patient care with regard to risk assessment, diagnosis and treatment. The conditions are not limited to but include cancer, cardiova

 
AEMD
0.200.00(0.00%)Apr 17 9:52 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.